appendiceal cancer
Recently Published Documents


TOTAL DOCUMENTS

131
(FIVE YEARS 54)

H-INDEX

14
(FIVE YEARS 3)

Author(s):  
Mary Garland-Kledzik ◽  
Anthony Scholer ◽  
Miquel Ensenyat-Mendez ◽  
Javier I. J. Orozco ◽  
Adam Khader ◽  
...  

Author(s):  
Mary Garland-Kledzik ◽  
Anthony Scholer ◽  
Miquel Ensenyat-Mendez ◽  
Javier I. J. Orozco ◽  
Adam Khader ◽  
...  

2021 ◽  
Vol 116 (1) ◽  
pp. S88-S88
Author(s):  
Anas Raed ◽  
Amol Sharma ◽  
Shreyu Umapathy ◽  
John Erikson Yap ◽  
Humberto Sifuentes ◽  
...  

2021 ◽  
Vol 116 (1) ◽  
pp. S88-S88
Author(s):  
Anas Raed ◽  
Amol Sharma ◽  
Subbaramia Sridhar ◽  
John Erikson Yap ◽  
Humberto Sifuentes

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Gang Wang ◽  
Qiken Li ◽  
Weiping Chen

Abstract Background Due to its rarity and high heterogeneity, neither established guidelines nor prospective data are currently available for using chemotherapy in the treatment of appendiceal cancer. This study was to determine the use of chemotherapy and its potential associations with survival in patients with different histological types of the cancer. Methods Patients with histologically different appendiceal cancers diagnosed during 1998–2016 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. The role and effect of chemotherapy were examined in the treatment of the disease. The Kaplan-Meier method was applied to construct survival curves and significance was examined by Log-rank test. Cox proportional hazard models were used to analyze the impact of chemotherapy and other variables on survival in these patients. Results A total of 8733 appendiceal cancer patients were identified from the database. Chemotherapy was administrated at highly variable rates in different histological types of appendiceal cancer. As high as 64.0% signet ring cell carcinoma (SRCC), 46.4% of mucinous adenocarcinomas (MAC), 40.6% of non-mucinous adenocarcinoma (NMAC) and 43.9% of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) were treated with chemotherapy, whereas only 14.7% of goblet cell carcinoma (GCC), 5% neuroendocrine tumors (NETs) and 1.6% carcinomas (NEC) received chemotherapy. In all patients combined, chemotherapy significantly improved overall survival during the entire study period and cancer-specific survival was improved during in cases from 2012–2016. Further multivariate analysis showed that both cancer-specific and overall survival was significantly improved with chemotherapy  in patients with MAC, NMAC and SRCC, but not for patients with GCC, MiNENs, NETs and NECs. Number (> 12) of lymph node sampled was associated with survival of patients with most histological types of cancer under study. Other prognostic factors related to individual histological types were identified. Conclusions Chemotherapy is administrated at highly variable rates in different histological types of appendiceal cancer. Efficacy of chemotherapy in the treatment of these cancers has been improved in recent years and is significantly associated with better survival for patients with NMAC, MAC, and SRCC. Adequate lymph node sampling may result in a survival benefit for most of these patients.


2021 ◽  
pp. clincanres.0982.2021
Author(s):  
Steven D. Forsythe ◽  
Richard A. Erali ◽  
Shyama Sasikumar ◽  
Preston Laney ◽  
Ethan Shelkey ◽  
...  

2021 ◽  
Author(s):  
Steven D. Forsythe ◽  
Richard A. Erali ◽  
Preston Laney ◽  
Shyama Sasikumar ◽  
Perry Shen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document